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Background: Patients with cystic fibrosis (CF) experience recurrent infections and develop 
chronically infected lungs, which initiates an altered immunological alveolar environment. End-
stage pulmonary dysfunction is a result of a long sequence of complex events in CF, progressing 
to alveolar macrophage dysfunction via a T-helper 2 (TH2) dominated alveolar inflammation 
with CD20 T-cell activation, induced by the chronic infection and showing a poor prognosis. 
There is great potential for treatment in transforming the TH2 into the more favorable T-helper 
1 (TH1) response.
Methods: Current literature in the PubMed database and other sources was reviewed in order 
to evaluate aspects of the innate alveolar host defense mechanisms and the potential impact on 
the immunoinflammatory response of inhalation of granulocyte-macrophage colony-stimulating 
factor (GM-CSF) in patients with CF.
Results: It seems that the cellular host defense, (ie, the alveolar macrophage and neutrocyte 
function) and the inhaled GM-CSF interact in such a way that the so-called tolerant alveolar 
environment dominated by the TH2 response may be transformed into an active TH1 state with 
a normal pulmonary host defense. The shift of the TH2 to the TH1 subset dominated by specific 
and unspecific antibodies may be achieved after the inhalation of GM-CSF. A clinical report has 
shown promising results with inhalation of GM-CSF in a chronically-infected CF patient treated 
with several antibacterial and antifungal agents. Inhaled GM-CSF transformed the tolerance 
toward the Gram-negative infection reflected by the so-called TH2 subset into the more acute 
TH1 response characterized by recruitment of the T-cells CD8 and CD16, a condition related to 
better-preserved lung function. This indicated a transformation from a state of passive bacterial 
tolerance toward the Gram-negative infecting and colonizing bacteria. This GM-CSF effect can-
not be achieved by administering the drug via the IV route because the drug is water-soluble 
and too large to penetrate the alveolocapillary membrane.
Conclusions: Inhalation of GM-CSF seems to be a novel way to positively modulate the alveolar 
environment toward an altered immunological state, reflected by a positive change in the pattern 
of surrogate markers, related to better preservation of pulmonary function and thus improved 
outcomes in CF patients. It is suggested that future studies examining standard endpoint vari-
ables such as number of infections and amount of antibiotics used should be supplemented by 
surrogate markers, to reveal any positive cellular and cytokine responses reflecting changes in 
the alveolar compartment after GM-CSF inhalation. The immunological alveolar environment 
should be monitored by a specific pattern of surrogate markers. Continued research is clearly 
indicated and the role of inhaled GM-CSF in modulating pulmonary host defense in CF patients 
should be investigated in a large study.
Keywords: cystic fibrosis, granulocyte-macrophage colony-stimulating factor, TH1 response, 
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Introduction
Patients with cystic fibrosis (CF) are subject to recurrent 
and chronic lung infections due to impairment of the natu-
ral host defenses of their airways.1 End-stage pulmonary 
dysfunction in CF is a result of a long sequence of recur-
rent infections and colonizations that induce alveolar mac-
rophage dysfunction via a T-helper 2 cell (TH2) dominated 
alveolar inflammation.2 The TH2 response is tolerant toward 
multiple infections.3
The cystic fibrosis transmembrane conductance 
regulator chloride channel (CFTR) plays a central role 
in bactericidal activity both in the neutrocyte and the 
macrophage. The defective CFTR-/- macrophages have 
reduced intra  cellular acidification and a Gram-negative 
infection initiates an alveolar TH2 response with B-cell 
activation resulting in antibody formation.4 In this way 
the response is transformed from the normal alveolar 
host defense into the well characterized immunologic 
and allergic alveolar disorder accompanied by increased 
systemic immunoglobulin formation, which contributes 
to the pathogenesis of CF.4 The TH2 response has been 
connected with an unfavorable and accelerated decline in 
lung function.5 End-stage alveolar macrophage dysfunc-
tion is reflected by reduced antigen (Ag) presentation,6 
enhanced tolerance toward lipopolysaccharide (LPS),1,7 
and reduced expression of recognition receptors, the so-
called toll-like receptors (TLR), where TLR4 recognizes 
Gram-negatives.8 The reduced alveolar host defense may 
also induce remodeling of the peripheral airways, lead-
ing to a fall in lung function which ultimately results in 
pulmonary failure.9 This pathogenic step is only seen to 
affect the pulmonary host defense: circulating monocytes 
that are not yet exposed to interaction in the specific 
pulmonary milieu seem unaffected, even though all host 
cells are supposed to be affected equally by the congenital 
CFTR mutation.10 Ongoing stimulation of the LPS binding 
receptor (CD14+) on the alveolar host cells causes receptor 
internalization and induces a state of LPS tolerance and 
subsequently hyperinflammation (Figure 1).1 The same 
unresponsiveness of the host cells is suspected in the 
sinuses, where a finding of chronic sinusitis with bacte-
rial colonization is almost ubiquitous in the CF patient,11 
potentially serving as a bacterial reservoir leading to 
recolonization of the lungs after antibacterial eradication 
of the lung infection.12
The dominant microbiological etiology of the chronic 
infections is Pseudomonas aeruginosa, Staphylococcus 
aureus, Burkholderia cepacia complex, Achromobacter xylo-
soxidans and Mycobacterium abscessus/chelonae. These are 
frequently isolated from CF lungs.13 Microorganisms such as 
P . aeruginosa find a niche in the alveolar environment due to 
a whole host of bacterial survival “strategies” – the so-called 
bacterial “stealth strategy” – including mucoid exopolysac-
charide production and biofilm formation, evading both the 
host defense system and antibiotic therapy. Once the lungs 
are chronically infected it is impossible to eliminate the 
causative agent. The ongoing colonization induces antibiotic 
resistance,14 which results in a continuous reduction of lung 
function due to destruction of the lung tissue induced by 
the excessive inflammation.15 A high or rapidly increasing 
number of anti-Pseudomonas antibodies has been correlated 
to a poor prognosis, while CF patients with a low number of 
anti-Pseudomonas antibodies show an improved outcome 
with chronic P . aeruginosa lung infection.16 TH-cells are 
subdivided into two subsets based on their cytokine pattern: 
TH1 pattern cells are characterized by IFN-γ, production and 
activation of macrophages, and induction of cellular T-cell 
responses. In contrast, the TH2 pattern produces IL-4, IL-5, 
IL-9, and IL-13 and is characterized by increased CD20 
T-cells (Table 1).17
Increased IL-4 and reduced IFN-γ release from periph-
eral blood mononuclear cells (PBMCs) stimulated with 
Pseudomonas antigen has been demonstrated.18
Inhaled GM-CSF and the TH1 subset
The beneficial TH1 subset may be induced by GM-CSF: 
T-lymphocytes are recruited into the alveolus as are antigen-
presenting alveolar macrophages. The TH2 subset caus-
ing the tolerance towards the ever-present Pseudomonas 
  species in the alveolar environment is downregulated by 
the inhaled GM-CSF. This makes inhaled GM-CSF a highly 
interesting new drug for inhalation with respect to alveolar 
  immunomodulation. In addition, inhaled GM-CSF stays in 
the alveolus with no spill-over to the circulation and thus has 
no systemic adverse effects.19
Research has shown that chronically-infected CF patients 
with the highest IFN-γ and IL-4 production also have the 
best-preserved lung function, indicating a beneficial potential 
for the modulation of the TH1/TH2 balance.10
Animal studies and modulation  
of the immune system
It has been documented that IFN-γ treatment of rats with 
chronic P . aeruginosa lung infection results in increased 
neutrophilic-induced pulmonary inflammation with less 
reactive mononuclear cells.24
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Figure 1 Pathogenesis of the complex series of events in cystic fibrosis (CF) progressing to alveolar macrophage dysfunction via a TH2 dominated alveolar inflammation.   
(A) Denotes the interaction between the defective cystic fibrosis transmembrane conductance regulator (CFTR)-/- macrophages in respect to intracellular acidification and 
Gram-negative infection, an interaction involving a T-cell switch (B) to an alveolar T-helper 2 response with induction of B-cell activation with antibody formation, transforming 
CF into an immunological allergic disease characterized by increased systemic immunoglobulin formation (IgG and Ige). The TH2 response has been connected with an 
unfavorable accelerated declined spirometry. The end stage of the altered alveolar environment (C) with alveolar macrophage dysfunction, reflected by (i) reduced antigen (Ag) 
presentation, (ii) enhanced tolerance toward lipopolysaccharide (LPS) and finally (iii) reduced expression of recognition receptors, the so-called toll-like receptors (TLR) where 
TLR-4, which recognizes Gram-negatives, is decreased. In the end, remodeling of peripheral airways will take place producing a reduced alveolar host defense.
Table 1 Comparison of two subsets TH1 and TH2 each consisting of T-cells and a corresponding cytokine pattern
Subset Characterization Clinical response Surrogate variables* References
TH1 Acute inflammatory response  
orchestrated by the AM***  
after GM-CSF activation
T-cell recruitment from systemic  
cellular pool via macrophage  
antigen presentation
T-cells:
CD8 and 16 
TH1 cytokines:
IL-12 and IFN-γ
Brazova et al10 
Eksioglu et al19 
Gonzalez-Juarrero et al20 
Moser et al18
Trapnell et al21
TH2 Chronic host response 
LPS tolerance 
Allergic response
Inflammatory response related  
to chronic infection/colonization 
Antibody producing cells  
via CD20 cells
T-cells:
CD20 + antibodies IgE** 
TH2 cytokines:
ILs 4 and 10
Brazova et al10 
Greenberger4
Knutsen et al22 
Meneghin and Hogaboam23
Spellberg and Edwards17
Notes: *Measurements performed in Bronchoalveolar lavage fluid (BALF); **Specific or unspecific antibodies measured in plasma; 
Abbreviations: AM, alveolar macrophage, which after inhaled GM-CSF is transformed by the inhaled GM-CSF into an immune inflammatory competent dendritic cell; 
GM-CSF, granulocyte-macrophage colony-stimulating factor.
A key cell in initiating and controlling the T-helper cell 
response is the dendritic cell (DC). Unless the DCs pres-
ent and interact, naive T-cells will not be activated.25 The 
resting alveolar macrophage will only be transformed into 
a DC if GM-CSF is present to stimulate the surface recep-
tor of the alveolar macrophages (the autocrine function).26 
It may be hypothesized that increased serum granulocyte 
colony-stimulating factor (G-CSF) could be the cause of 
the skewed TH1/TH2-ratio observed in CF. Moreover, several 
publications have reported that granulocyte GM-CSF can 
induce a TH1 dominated response through modulation of 
the DCs.27,28 Indeed, chronically-infected CF patients were 
observed to have a significantly decreased GM-CSF/G-CSF 
ratio as compared to CF patients without a chronic P . aerugi-
nosa lung infection.5 Furthermore, this GM-CSF ratio corre-
lated to the IFN-γ release from peripheral blood mononuclear 
cells (PBMCs) and lung function, indicating a beneficial role 
for GM-CSF treatment in CF. GM-CSF is normally produced 
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locally by the alveolar macrophages,21 being the first line of 
defense when clearing bacteria.29 The innate immune func-
tion of the alveolar macrophage is significantly influenced by 
subsequently acquired immune responses.30 The concentration 
of GM-CSF in the alveolar space is of utmost importance for 
the pulmonary host defense system.
Treatment of CF patients has hitherto focused on 
intensive long-term, high-dose, broad-spectrum antibiotics 
administered intravenously and by inhalation, combined 
with interventions aiming at enhanced clearance of mucus, 
eg, with DNA-ase.
Inhalation versus intravenous  
administration
Recently a paper discussed whether recombinant proteins 
should be inhaled or administered systemically in order to 
reach an alveolar target.31 In the context of the present review 
one may question which route of administration should be 
preferred, when one intervenes with GM-CSF.
It has been documented that inhaled GM-CSF increases 
the number and function of phagocytic cells obtained from 
bronchoalveolar lavage (BAL), but with only sparse and tran-
sient increase in the number of myeloid cells in circulation.32 
Conversely, when administered intravenously (IV) there 
was only a limited response in alveolar cellularity. It follows 
that the pulmonary innate host defense is separated from the 
systemic defense system with respect to GM-CSF, and that 
the agent does not penetrate from the systemic circulation to 
the alveolar space or vice versa.32 IV administration of even 
relatively small molecules like recombinant antitrypsin does 
not reach the alveolar space, as shown by the fact that only 
2% of the IV-administered drug reaches the lung space.33 
For larger molecules like the recombinant protein Activated 
Protein C (APC), it has been documented that administered 
intravenously, APC had no effect even in the inflamed lung.34 
However, when inhaled, APC achieved the expected effect in 
the alveolus, without any systemic adverse effects.35,36
GM-CSF neutralizing autoantibodies in pulmonary alveo-
lar proteinosis (PAP) have led to a lack of phagocytic func-
tion of alveolar macrophages.37 Subcutaneous administration 
of GM-CSF has been tried in PAP to improve macrophage 
function, but only inhaled GM-CSF had an effect.38 The 
explanation is that anti-GM-CSF blocking autoantibodies 
are detected both in serum and BAL fluid from patients 
with PAP.39
A major point is the question of whether the inhaled drug 
reaches the GM-CSF receptors of alveolar macrophages in 
the peripheral airways.
By using a so-called micropump nebulizer, sufficiently 
small respirable aerosol particles with a size of ∼2.5 µm are 
produced, which means that a high degree of peripheral lung 
deposition is obtained.40,41 Inhaled GM-CSF also appears safe 
because aerosol therapy did not cause any adverse effects 
in either lung cancer or in patients with pulmonary alveolar 
proteinosis.42–44 Based on these findings GM-CSF treatment 
may therefore be best inhaled rather than administered 
systemically.
Immunomodulatory treatment
Treating CF patients with GM-CSF inhalation has shown 
promising results.45 The drug was inhaled in a dose of 
250 µg/day for 1 week followed by 14 days’ pause, for a total 
period of 3 months. The GM-CSF response was monitored 
by immunoglobulins IgG and IgE, cytokines, and spirometry 
(forced expiratory volume in 1 second, FEV1). Interestingly, 
it brought about a noteworthy cytokine increase, ie, an IFN-γ 
increase from PBMCs activated with bacterial antigen.
Inhalation of GM-CSF was well tolerated without any 
signs or symptoms of pulmonary adverse effects, such as 
bronchoconstriction. The treatment seemed safe. None of 
the described findings following inhalation were documented 
after systemic GM-CSF therapy: ie, no switch in T-helper 
cell pattern and no change in immunologic allergic variables 
or cytokine response. It was not possible to document any 
effect in the alveolar space when systemic administration of 
GM-CSF or other biologics was used. These findings sup-
port the concept that the inhaled GM-CSF transformed the 
TH2 dominated alveolar condition into a TH1-like response 
(Table 1), a suggestion which is also in keeping with the fact 
that a TH2 response is seen when Aspergillus antigens appear 
in CF patients.22 During the period of inhaled GM-CSF inter-
vention, a noteworthy increase in IFN-γ release of PBMCs 
after stimulation with Mycobacterium abscessus antigen was 
noted, a TH1 response which was not demonstrated during 
systemic GM-CSF administration.
Furthermore it has been documented that transgenic 
mice overexpressing GM-CSF in alveolar epithelial cells 
have an enhanced resistance towards influenza by activa-
tion of the alveolar immune mechanisms that depend on 
alveolar macrophages.46 These mice were highly resistant 
to infection with laboratory and clinical influenza strains, 
including the pandemic swine H1N1 strain. The mice had 
reduced lung injury and reduced mortality after influenza 
infection. They also showed increased levels of TNF-α and 
evidence of mononuclear cell infiltrates after infection. The 
histological findings suggested that the mice mounted a rapid 
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host-immune response to influenza infection. These results 
indicate that the host response reduced the viral burden and 
most importantly reduced the mortality of the infection, 
emphasizing the therapeutic potential of inhaled GM-CSF.
Should host defense or total lung  
function be used as endpoints?
It has been predicted that the TH1 subset, increased by inhaled 
GM-CSF, is related to a much more favorable FEV1 and 
vital capacity (VC) in the longer run.5 Further, the change 
in FEV1 does not sufficiently and sensitively reflect changes 
in the peripheral airways, because small airways normally 
contribute less than 30% of the total airway resistance.47 
This implies that substantial abnormalities could arise in 
these airways before the FEV1 becomes abnormal.48,49 It thus 
appears that measurement of total lung function (FEV1 and 
VC) does not, over a longer time span, reflect the changes of 
the small airways and alveolar environmental changes with 
sufficient sensitivity during the chronic infectious state. This 
is a most important point in the documentation of changes 
induced by inhaled GM-CSF, because GM-CSF exerts 
its effect on the alveolar macrophages. It therefore seems 
irrelevant to measure total lung function variables in order 
to reflect modifications after interventions such as inhaled 
GM-CSF, because measurements of FEV1/VC in a much 
later, irreversible phase reflect restrictive pulmonary dysfunc-
tion, such as extensive irreversible structural remodeling of 
small airways, with widespread bronchiectases, cyst forma-
tion, mucoid impaction, atelectasis, fibrosis, and vascular 
changes.50 Alternative methods reflecting the immunological 
changes that prevent irreversible lung function damage must 
therefore be applied. The measurement of total lung function 
should therefore be abandoned because it is irrelevant in 
respect to the prevention of fibrosis in the CF patient. Lung 
function testing should not be the monitor – on the contrary 
it is only the endpoint. Therefore the monitor should be the 
pathophysiologic variables that prevent lung fibrosis: the 
surrogate variables as shown in Table 2, which reflect the 
multiple efficacy aspects of inhaled GM-CSF.
Discussion
Treating chronic lung infections in patients with CF becomes 
an increasing challenge in spite of the increasing use of both 
systemic and inhaled administered antibiotics. CF patients 
develop intolerance and allergic reactions to a number of 
antibiotics, along with reduction of renal and hepatic func-
tion. Since lung tissue damage is highly associated with 
the inflammatory reaction induced by infection, adjunctive 
immuno-modulators have increasingly been considered as 
necessary treatment options in CF.51
Since antibacterial and anti-inflammatory interventions 
have not led to the expected result, a paradigm shift is needed. 
Treatment with GM-CSF could be such a new paradigm 
because its mechanism of action aims at the upregulation of 
the alveolar host defense. Here, the functions of the alveolar 
macrophages are considered most important in respect to 
the alveolar host defense towards bacteria and fungi, because 
the alveolar environment is dominated by tolerance toward the 
Gram-negatives – the so-called T-helper subset TH2; a state 
which is characterized by the chronic invasion of CD20 cells 
into the alveolar space, which is reflected by the increased 
immunoglobulins IgG and IgE.52 Inhalation of the growth fac-
tor GM-CSF causes a transformation into the TH1 dominated 
subset, a change which could upregulate the pulmonary host 
defense even in the chronically-infected CF patient.
Alveolar host defense and the alveolar  
environment
The Achilles heel of CF is the infected lung with reduced 
clearance of bacteria, fungi, and viruses, causing progres-
sive lung disease associated with unremitting bacterial 
infection, predominantly P . aeruginosa.53 The gene defect 
in CF affects macrophages globally due to the lack of CFTR 
regulation, reducing the important phagosomal   acidification 
Table 2 Overview of potential surrogate markers in relation to monitoring the efficacy of inhaled GM-CSF
Overall Variable Sampling
Inflammation NO exhaled Expiratory air sampling
Eosinophilic toxin Urine concentration of eosinophilic   
degradation products
Cytokines IL-2, 4, 5, 10 og 12, IFN-γ, TNF Blood
Antibodies IgE, IgG Blood
Cells Recruited from BAL fluid FACS analysis
Biofilm formation QS and CFU threshold in relation to biofilm  
formation monitored by sputum alginate
QS, in vitro test   
Alginate in sputum ELISA-test
Abbreviations: QS, Quorum sensing; CFU, colony forming unit; BAL, bronchoalveolar lavage; eLISA, enzyme-linked immunosorbent assay; FACS, fluorescence activated 
cell sorting.
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and causing a reduced bactericidal activity triggered by 
the altered alveolar microenvironment, as underlined by 
the fact that the CF patient does not have an increased rate 
of systemic infections.54 Loss of intracellular acidification 
in CFTR-deficient alveolar macrophages could therefore 
be the explanation for the enhanced survival of bacterial 
loads within the phagosomal compartment.55 This appar-
ent discrepancy between reduced alveolar macrophage 
function and lack of global infections may seem puzzling. 
However, the interaction between CFTR-affected alveolar 
macrophages and Gram-negative pulmonary infection 
precipitates a regionally-reduced pulmonary host defense. 
Normally alveolar macrophages induce inflammatory 
cytokines after exposure to Gram-negative bacteria via the 
TLRs. However, in CF patients, TLR4 expression in the 
bronchial epithelium is significantly reduced compared to 
healthy control subjects, which is emphasized by the find-
ing that the TLR4 surface expression is normalized after 
correction of the CFTR-negative cells.8 The loss of CFTR 
function appears to decrease innate immune responses, 
possibly by altering the expression of TLR4 on airway 
epithelial cells, thereby contributing to chronic bacterial 
infection in CF airways.8
The defective macrophage and the 
alveolar environment in the CF patient
In a mouse model of CF based on mice infected with LPS, 
a defect in CF macrophage function has been suggested. 
The innate GM-CSF expression was reduced in CF-like 
mice as compared to wild-type mice,56 in line with the find-
ings of increased mortality, and reduced phagocytosis and 
intracellular bacterial killing of Gram-negatives by alveolar 
macrophages in GM-CSF (-/-) mice. By administering GM-
CSF, the documented changes were reversed.57
Along with the documented dysfunctional macrophages 
of the CF lung, which could explain the reduced capacity to 
clear bacterial infecting agents, the end result could be an 
excessive chronic inflammatory response, the TH2 dominated 
response.
The alveolar cellular recruitment process may lead to 
either a TH1 or a TH2 cell response. The TH1 response enhances 
a cellular profile with cytotoxic T-cells (CD8+) and natural 
killer cells (CD16+ (NK-cells)), with a specific cytokine 
IFN-γ pattern,10 whereas the TH2 response corresponds to a 
chronic hyperinflammatory state with a different cytokine 
profile and recruitment of CD20+ cells with production of 
immunoglobulins (Table 1), triggered by ongoing stimulation 
of the antigens mostly from Pseudomonas spp.10
The chronic local inflammatory state is dominated by 
the TH2 response, with activation of CD20+ cells, increased 
production of antibodies, and development of tolerance 
towards Gram-negative infections.4 With the alveolar toler-
ance towards Gram-negative bacteria, the CD14 cells char-
acteristic of the TH2 subset induce irreversible lung fibrosis 
and pulmonary dysfunction typical of CF terminal respiratory 
insufficiency.23
Effect of inhaled GM-CSF
Inhaled GM-CSF can potentially enhance the complex 
host defense of the alveolar environment, because the 
drug enhances macrophage function via multiple points of 
action. (i) The TLR4 s acting on Gram-negative bacteria are 
increasingly expressed after treatment with GM-CSF, which 
facilitates the recognition and clearing of Gram-negatives.58 
(ii) The drug increases alveolar antigen presentation by 
enhanced opsonization and intracellular killing of bacteria 
after GM-CSF administration.19 (iii) The local GM-CSF has 
been shown to shift T-helper response toward the essential 
TH1 subset, because the recruited cytotoxic (CD8) and 
NK-cells (CD16) from the systemic circulation may clear 
the infection.20,21 (iv) Inactivation of pulmonary fibroblasts 
(CD14). These factors combine to produce a more favorable 
lung function outcome.5
It also appears likely that bacterial clearance is improved 
by a T-helper cell switch from an immunological TH2 
response to the favorable TH1 setting. It appears that such 
a shift takes place during and after the GM-CSF inhala-
tion period as both IgG and IgE are reduced and specific 
IgE anti-Aspergillus antibodies are reduced during the 
inhalation period.5
The antibody response against P . aeruginosa in CF is a 
marker of chronic infection, inflammation, and tissue dam-
age. The very high sensitivity of the assays makes it possible 
to characterize patients with negative antibody assays as 
being free of chronic P . aeruginosa infection.59 The TH2-
like immunological response also encompasses an allergic 
component with increased immunoglobulins that is typical 
for allergic bronchopulmonary aspergillosis. This condition 
is common in CF, with an incidence of 10%. The condition 
is diagnosed by increased levels of IgE, Aspergillus-specific 
IgE and IgG, or precipitins.60 Cohen-Cymberknoh et al found 
that treatment with prednisolone, which is supposed to be 
the treatment of choice, did not suppress the antibodies.61 
With GM-CSF inhalation, on the other hand, IgE fell to 
almost zero and the IgG leveled out. Further it appeared that 
macrophage function was enhanced, because A. fumigatus was   
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not cultured and acid-fast bacteria could not be detected in the 
patients’ sputum for a period after the GM-CSF inhalation.
These findings strongly support the concept that inhaled 
GM-CSF transforms the TH2-dominated alveolar condition 
into a TH1-like response, which is in keeping with the fact 
that a TH2 response is seen when Aspergillus antigens appear 
in CF patients.22 During the GM-CSF inhalation period, 
stabilization of lung function (FEV1) was noted.45 However, 
changes in FEV1 do not sufficiently and sensitively reflect 
changes in the peripheral airways because small airways 
normally contribute less than 30% of the total airway resis-
tance.47 Therefore substantial abnormalities could arise in 
these airways before FEV1 values become abnormal.48 It 
appears that measurements of FEV1 do not sensitively reflect 
changes in the environment of small airways in early stages 
of the disease – the point of attack of inhaled GM-CSF. 
Later however, FEV1 values reflect respiratory failure due 
predominantly to extensive irreversible structural remodel-
ing of the small airways, with widespread bronchiectases, 
cyst formation, mucoid impaction, atelectasis, fibrosis, and 
vascular changes.50 In future, measurements of FEV1 should 
be combined with immunological variables (ie, surrogate 
variables). Inhaled GM-CSF did not produce pulmonary 
adverse effects in any of the published papers documenting 
the adverse effects of GM-CSF, ie, neither wheezing nor signs 
of bronchoconstriction were registered.
Inhaled GM-CSF also appears safe because aerosol 
therapy did not cause any adverse effects in either lung cancer 
or in patients with pulmonary alveolar proteinosis.42–44
Surrogate markers reflecting the changes 
in the alveoli
Table 2 shows the multiple points of action of inhaled GM-
CSF as they relate to future studies, most of which are aimed 
at monitoring the TH2 to TH1 switch.
These variables could provide a new approach to studying 
alterations in the alveolar environment after an intervention 
such as treatment with inhaled GM-CSF.
A major issue in the antibacterial strategy is that biofilm 
formation protects bacteria from antibiotic action. In CF 
patients there is frequent colonization with P . aeruginosa 
and the mucoid isolate forms a biofilm of which a major 
component is alginate. This may quantitatively be measured 
in sputum (Table 2). The mucoid isolate is a Pseudomonas 
strain that constantly signals neighboring bacteria via phero-
mones to produce biofilm. These colony forming units (CFU) 
can produce biofilm by increasing the bacterial density by a 
process called quorum sensing (QS).62
This adaptive “stealth” strategy counteracts the combined 
antibacterial action of antibiotics and the endogenous alveolar 
immune system.
Treatment of the mucoid strains has hitherto not been 
able to counteract the biofilm formation. Because inhaled 
GM-CSF can upregulate the peripheral airways host defense, 
it could, just by reducing the CFUs, reduce the amount of 
alginate in sputum. The in vitro QS test could prove to be a 
useful marker of the efficacy of GM-CSF inhalation.
Conclusion
Inhaled GM-CSF seems to be a promising new treatment 
to improve host defenses in patients with CF. The chronic 
alveolar immuno-inflammatory status with colonization 
is a typical TH2-dominated inflammatory response. Such 
a subset unfortunately appears to be tolerant of Gram-
negative bacteria. After inhalation of GM-CSF, however, 
the T-helper cells can be transformed into the TH1 subset, 
as documented by reduced immunoglobulin IgG and IgE 
concentration in a recent study.45 The IgE concentration, 
which is related to allergy, was also reduced after GM-CSF 
inhalation, indicated by an altered cytokine pattern that 
showed increased TNF, IL-1β, IFN-γ, and IL-10 concentra-
tion. Inhaled GM-CSF was regarded as the only effective 
administration route because IV-administered GM-CSF, 
like other biologics, does not pass the alveolocapillary 
membrane. This important fact makes it possible to achieve 
a direct effect on the alveolar immune inflammatory 
response without adverse effects in the systemic pool of 
immunoactive cells.
In order to elucidate the role of inhaled GM-CSF in a 
human controlled trial, at least in a short term study of 6 
weeks, it is necessary to apply not only the classical pri-
mary endpoints but to supplement with changes in specific 
surrogate variables each reflecting a specific function of 
the host system. In such a study we find it less important to 
emphasize classical spirometry measurements as the primary 
endpoint. The expected alterations in lung function do not 
reflect the changes in peripheral airways and the alveolar 
environment after administration of inhaled GM-CSF. The 
overall purpose of such a study is to show that inhaled 
GM-CSF in chronically colonized CF patients modifies the 
immuno-inflammatory state and switches the TH2 subset into 
the favorable TH1 subset.
Continued research is clearly indicated and the role of 
inhaled GM-CSF in modulating the pulmonary host defense 
in CF patients should be investigated in a large controlled 
study.
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